Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine

Mitragynine, the most abundant active component found in the leaves of Mitragyna speciosa, has been proposed to use as pain and opiate withdrawal symptoms reliever. Even though it had been banned in certain countries, however, some people still consume it for different medical indications. In recent...

Full description

Bibliographic Details
Main Author: Chik, Z.
Format: Conference or Workshop Item
Language:English
Published: 2017
Subjects:
Online Access:http://eprints.um.edu.my/18533/1/Effects_of_cytochrome_P450_%28CYP%29_2D6_inhibitions_in_in_vivo_toxicity_studies_of_mitragynine..pdf
_version_ 1796960507813429248
author Chik, Z.
author_facet Chik, Z.
author_sort Chik, Z.
collection UM
description Mitragynine, the most abundant active component found in the leaves of Mitragyna speciosa, has been proposed to use as pain and opiate withdrawal symptoms reliever. Even though it had been banned in certain countries, however, some people still consume it for different medical indications. In recent years, it has been strongly related to drug abused and several reported death cases. In our study, the effects of CYP2D6 on mitragynine’s metabolism and drug-drug interaction (DDI)-induced toxicity were investigated intensively using quinidine, a CYP2D6 inhibitor. The findings showed that coadministration of 10 mg/kg quinidine increased the mitragynine elimination half-life and area under the curve significantly using a conventional pharmacokinetic study. The experiment was extended with in vivo 14-days toxicity study at highest dose 50 mg/kg of mitragynine. Lethal dose of 300 mg/kg mitragynine alone was identified in the pilot study. Whereas, mortality rate of mitragynine (4 out of 6 rats) at 50 mg/kg was dramatically increased in the presence of quinidine as compared with mitragynine control. Liver markers such as AST and ALT were also significantly elevated at the dose as low as 5 mg/kg with quinidine co-administration. Lastly, histopathological analysis showed inflammatory cell infiltration in both of liver and kidney at highest tested dose. In conclusion, CYP2D6 plays the major role in phase I metabolism of mitragynine and it strongly associated with the DDI-induced mortality, as well as hepatotoxicity. Therefore, concurrent administration of mitragynine and drugs which are inhibitors of the CYP2D6 enzyme would increase fatality among mitragynine consumers or abusers.
first_indexed 2024-03-06T05:45:40Z
format Conference or Workshop Item
id um.eprints-18533
institution Universiti Malaya
language English
last_indexed 2024-03-06T05:45:40Z
publishDate 2017
record_format dspace
spelling um.eprints-185332018-04-25T01:34:33Z http://eprints.um.edu.my/18533/ Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine Chik, Z. R Medicine RM Therapeutics. Pharmacology Mitragynine, the most abundant active component found in the leaves of Mitragyna speciosa, has been proposed to use as pain and opiate withdrawal symptoms reliever. Even though it had been banned in certain countries, however, some people still consume it for different medical indications. In recent years, it has been strongly related to drug abused and several reported death cases. In our study, the effects of CYP2D6 on mitragynine’s metabolism and drug-drug interaction (DDI)-induced toxicity were investigated intensively using quinidine, a CYP2D6 inhibitor. The findings showed that coadministration of 10 mg/kg quinidine increased the mitragynine elimination half-life and area under the curve significantly using a conventional pharmacokinetic study. The experiment was extended with in vivo 14-days toxicity study at highest dose 50 mg/kg of mitragynine. Lethal dose of 300 mg/kg mitragynine alone was identified in the pilot study. Whereas, mortality rate of mitragynine (4 out of 6 rats) at 50 mg/kg was dramatically increased in the presence of quinidine as compared with mitragynine control. Liver markers such as AST and ALT were also significantly elevated at the dose as low as 5 mg/kg with quinidine co-administration. Lastly, histopathological analysis showed inflammatory cell infiltration in both of liver and kidney at highest tested dose. In conclusion, CYP2D6 plays the major role in phase I metabolism of mitragynine and it strongly associated with the DDI-induced mortality, as well as hepatotoxicity. Therefore, concurrent administration of mitragynine and drugs which are inhibitors of the CYP2D6 enzyme would increase fatality among mitragynine consumers or abusers. 2017 Conference or Workshop Item PeerReviewed application/pdf en http://eprints.um.edu.my/18533/1/Effects_of_cytochrome_P450_%28CYP%29_2D6_inhibitions_in_in_vivo_toxicity_studies_of_mitragynine..pdf Chik, Z. (2017) Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine. In: 2nd International Conference on Generic Drugs and Biosimilars (Generic-Biosimilars 2017), 14-16 December 2017, Rome, Italy. https://doi.org/10.4172/2161-1459-C1-025
spellingShingle R Medicine
RM Therapeutics. Pharmacology
Chik, Z.
Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine
title Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine
title_full Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine
title_fullStr Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine
title_full_unstemmed Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine
title_short Effects of cytochrome P450 (CYP) 2D6 inhibitions in in vivo toxicity studies of mitragynine
title_sort effects of cytochrome p450 cyp 2d6 inhibitions in in vivo toxicity studies of mitragynine
topic R Medicine
RM Therapeutics. Pharmacology
url http://eprints.um.edu.my/18533/1/Effects_of_cytochrome_P450_%28CYP%29_2D6_inhibitions_in_in_vivo_toxicity_studies_of_mitragynine..pdf
work_keys_str_mv AT chikz effectsofcytochromep450cyp2d6inhibitionsininvivotoxicitystudiesofmitragynine